Rochester University’s Organ-on-a-Chip Adopted by FDA ISTAND Program to Predict Immunotherapy Toxicity, Reducing Animal Testing

August 23, 2026

The Debrief USA

Overview

Researchers at the University of Rochester have developed an organ-on-a-chip, the µSiM tissue chip, which has been accepted into the FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program. This platform integrates ultrathin membranes with human cells and real-time sensors to predict dangerous immunotherapy side effects, such as cytokine release syndrome (CRS), without relying on animal models. This breakthrough offers a potential alternative to animal testing, accelerating drug development and addressing ethical and efficiency concerns.

In Depth

Key Findings

A novel organ-on-a-chip platform, the µSiM tissue chip, developed by researchers at the University of Rochester, has been accepted into the U.S. Food and Drug Administration’s (FDA) Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program. This platform demonstrates the potential to predict adverse inflammatory responses, such as cytokine release syndrome (CRS), associated with cancer immunotherapies in real-time and without animal testing, marking a significant advancement in drug development safety assessment.

Technical / Clinical Details

The µSiM tissue chip is a modular platform featuring human cells cultured on an ultrathin, biocompatible membrane, integrated with sophisticated sensors for real-time monitoring of inflammatory signals. This design precisely mimics the in vivo microenvironment, allowing for detailed tracking of cytokines and other inflammatory mediators. Crucially, it enables the evaluation of the effects of existing and novel immunotherapy candidates on human cells, free from the confounding variables of animal individual differences or species-specific variations. This significantly enhances the accuracy of predicting clinical adverse events, such as life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The technology is expected to contribute to the early detection and elucidation of mechanisms behind these severe side effects, thereby supporting the development of safer therapeutic strategies.

Background & Context

For decades, drug safety assessment in pharmaceutical development has heavily relied on animal testing. However, animal models present ethical concerns, limitations in translatability to humans due to species differences, and come with high costs and lengthy timelines. The FDA’s ISTAND program actively seeks to evaluate and embrace innovative non-animal testing approaches to address these challenges. The acceptance of the Rochester University organ-on-a-chip clearly demonstrates the potential of microfluidics and biosensing technologies to surpass conventional models in drug screening and toxicity prediction. Immunotherapies, while highly effective, are often associated with severe side effects, making their prediction and management a pressing challenge in the field.

Strategic Significance & Outlook

This organ-on-a-chip technology holds immense promise for streamlining drug development pipelines and reducing associated costs. Its acceptance into the FDA’s ISTAND program suggests that this technology could gain widespread recognition as a reliable alternative to animal testing data, or even a superior one, in future regulatory approval processes. Beyond cancer immunotherapy, the platform is expected to find applications in evaluating the safety and efficacy of drugs in other disease areas and for predicting patient-specific drug responses in the context of personalized medicine. This technology is poised to make substantial contributions to animal welfare and the accelerated market entry of safer, more effective medicines, thereby impacting global healthcare significantly.

Source: https://thedebrief.org/scientists-develop-organ-on-a-chip-that-could-reduce-the-need-for-animal-testing/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.